Skip NavigationSkip to Content

Lipidic inhibitors of human N-myristoyltransferase

  1. Author:
    Pasha, M. K.
    Selvakumar, P.
    Ashakumary, L.
    Qureshi, M.
    Guziec, F. S.
    Dimmock, J. R.
    Felsted, R. L.
    Glover, C. J.
    Sharma, R. K.
  2. Author Address

    Sharma, RK, Univ Saskatchewan, Hlth Res Div, Dept Pathol, Coll Med, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada Univ Saskatchewan, Hlth Res Div, Dept Pathol, Coll Med, Saskatoon, SK S7N 4H4, Canada. Univ Saskatchewan, Canc Res Unit, Hlth Res Div, Saskatoon, SK S7N 4H4, Canada. Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK S7N 4H4, Canada. SW Univ, Dept Chem, Georgetown, TX USA. NCI, Frederick Canc Res & Dev Ctr, Screening Technol Branch,Dev Therapeut Program, Div Canc Treatment & Diagnosis, Frederick, MD 21701 USA.
    1. Year: 2004
  1. Journal: International Journal of Molecular Medicine
    1. 13
    2. 4
    3. Pages: 557-563
  2. Type of Article: Article
  1. Abstract:

    This study was undertaken in order to identify compounds which inhibit the activity of human myristoyl-CoA:protein N-myristoyltransferase (hNMT). In particular, the structural features of such molecules which contribute to enzyme inhibition were investigated. Two groups of compounds, namely myristic acid and analogs 1-13 and derivatives of myristoyl-CoA 14-19 were evaluated. All compounds were examined using cAMP-dependent protein kinase derived peptide substrate. The IC50 values were <1 muM, between 1 and 100 muM or >100 muM in eight, four and seven compounds, respectively. Of the six myristoyl-CoA analogs, five had IC50 values in the 0.06-0.59 muM range. These molecules were examined using three additional substrates viz pp60(src), MARCKS and M2 gene segment of reovirus type 3 which led to results similar to those obtained with the cAMP-dependent protein kinase substrate. On the other hand, evaluation of myristic acid and four related compounds revealed some differences in hNMT-inhibiting properties among the substrates. From the results obtained, the possible manner whereby potent inhibitors interact with the enzyme was formulated thus enabling the design of further analogs as candidate inhibitors of hNMT

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel